Vol. 3 No. 1 (2023)
Reimbursement Reviews

Lutetium (¹⁷⁷Lu) Oxodotreotide (Lutathera)

decorative image

Published January 31, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses lutetium oxodotreotide (Lutathera), 370 MBq/mL at calibration, sterile solution for IV infusion.
  • Indication: For the treatment of unresectable or metastatic, well-differentiated, SSR (somatostatin receptor)-positive gastroenteropancreatic neuroendocrine tumours (NET) in adults with progressive disease.